Você procurou por: isplitusiu (Lituano - Inglês)

metastazmis ­ kauluose isplitusiu vziu) ,
cancer that has spread to the bone) ,

trumpino laik iki naviko progresavimo isplitusiu galvos ir kaklo vziu sergantiems
· shortened time to tumour progression in patients with advanced head and neck cancer patients

isgyvenamumas be ligos progresavimo sergant lokaliai isplitusiu vziu pagal gydymo pogrupius
progression-free survival in locally advanced disease by therapy sub-group

· vietiskai isplitusiu ar metastazavusiu nesmulkij lsteli plauci vziu, kuris neturi poveikio
· advanced or metastatic ` non-small cell'lung cancer that is not affecting the ` squamous'cells.

· metastaziniu (is pirminio zidinio kitas kno dalis isplitusiu) kiausidzi vziu.
· metastatic cancer of the ovary (when the cancer has spread to other parts of the body) .

erbitux skiriamas kartu su radioterapija gydyti pacientams, sergantiems lokaliai isplitusiu galvos ir kaklo vziu.
erbitux can be used for locally advanced cancers of the head and neck, when it is given in combination with radiation therapy (radiotherapy) .

visi pacientai sirgo vietiskai isplitusiu arba metastazavusiu nesmulkij lsteli plauci vziu ir jau buvo gydyti chemoterapiniais preparatais.
all patients were diagnosed with locally advanced or metastatic non-small cell lung cancer and received prior chemotherapy.

pripazinta, kad is esms statistiskai reiksmingo isgyvenamumo rodiklio, sergant lokaliai isplitusiu prostatos vziu, nustatyti nepavyko.
it is acknowledged that overall there is no statistically significant survival benefit in locally advanced prostate cancer.

vieno tyrimo metu 30 minuci trukms 175 mg/m2 abraxane infuzija buvo skiriama 43 ligoniams, sergantiems isplitusiu krties vziu.
in one study, abraxane was administered as a 30-minute infusion at a dose of 175 mg/m2 to 43 patients with metastatic breast cancer.

antrojo tyrimo metu 63 ligoniams, sergantiems isplitusiu krties vziu, 30 minuci trukms infuzijos bdu buvo skiriama 300 mg/m2 doz.
the second trial utilised a dose of 300 mg/m2 as a 30 minute infusion in 63 patients with metastatic breast cancer.

isplitusiu krties vziu sergantiems ligoniams ven suleidus rekomenduojam klinikin 260 mg/m2 abraxane doz, paklitakselio koncentracija kraujo plazmoje sumazjo daugiafaziu bdu.
following intravenous administration of abraxane to patients with metastatic breast cancer at the recommended clinical dose of 260 mg/m2, paclitaxel plasma concentrations declined in a multiphasic manner.

nauda is esms priklauso nuo progresavimo rizikos lokaliai isplitusiu vziu sergantiems pacientams; atlikus operacij arba jeigu gydymas spinduliniu bdu atrodo skmingas, gydymo vaistu nauda yra mazesn.
benefit is generally a function of risk progression and in patients with locally advanced disease; benefit is reduced after surgery or in cases where radiotherapy is likely to be curative.

tyrime, kuriame dalyvavo 511 vietiskai isplitusiu arba metastazavusiu krties vziu serganci moter, xeloda su docetakseliu derinio poveikis buvo lyginamas su docetakselio, vartojamo vieno, poveikiu.
in locally advanced or metastatic breast cancer, xeloda with docetaxel has been compared with docetaxel on its own in 511 women.

avastin derinant su interferonu alfa-2a skiriama kaip pirmojo pasirinkimo vaisto pacientams, sergantiems isplitusiu ir (arba) metastazavusiu inkst lsteli vziu.
avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and/or metastatic renal cell cancer.

(8, 7 mmol/l) , isplitusiu galvos ir kaklo vziu sergantiems pacientams, kuriems taikoma radioterapija, laikas iki naviko progresavimo sutrumpjo;
radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l) ,